One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Cultivating the Research Landscape for Critical Care Cardiology: The Case for Registry-Based Randomized Controlled Trials.
Sinha, Shashank S. MD, MSc; Katz, Jason N. MD, MHS; Morrow, David A. MD, MPH
doi : 10.1161/CIRCULATIONAHA.122.060802
Volume 147(22) pgs. 1637-1730 May 30, 2023
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos, Gerasimos MD; Ponikowski, Piotr MD, PhD; Farmakis, Dimitrios MD, PhD; Anker, Stefan D. MD, PhD; Butler, Javed MD, PhD; Fabien, Vincent PhD; Kirwan, Bridget-Anne PhD; Macdougall, Iain C. MD, PhD; Metra, Marco MD, PhD; Rosano, Giuseppe MD, PhD; Ruschitzka, Frank MD, PhD; van der Meer, Peter MD, PhD; Wachter, Sandra PhD; Jankowska, Ewa A. MD, PhD; on behalf of the AFFIRM-AHF Investigators
doi : 10.1161/CIRCULATIONAHA.122.060757
Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose (FCM), although having no significant effect on the primary end point, reduced the risk of HF hospitalization (hHF) and improved quality of life versus placebo in iron-deficient patients stabilized after an acute HF (AHF) episode
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Hundertmark, Moritz J. MD, DPhil; Adler, Amanda PhD; Antoniades, Charalambos MD; Coleman, Ruth MSc; Griffin, Julian L. DPhil; Holman, Rury R. MB, ChB; Lamlum, Hanan DPhil; Lee, Jisoo MD; Massey, Daniel MSc; Miller, Jack J.J.J. DPhil; Milton, Joanne E. PhD; Monga, Shveta MD, DPhil; Mozes, Ferenc E. DPhil; Nazeer, Areesha PhD; Raman, Betty MD, DPhil; Rider, Oliver MD, DPhil; Rodgers, Christopher T. DPhil; Valkovic, Ladislav PhD; Wicks, Eleanor MD, PhD; Mahmod, Masliza MD, DPhil ,*; Neubauer, Stefan MD ,,*
doi : 10.1161/CIRCULATIONAHA.122.062021
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction.
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
Yeoh, Su Ern MBChB ,*; Docherty, Kieran F. MBChB, PhD ,*; Campbell, Ross T. MBChB, PhD; Jhund, Pardeep S. MBChB, MSc, PhD; Hammarstedt, Ann PhD; Heerspink, Hiddo J.L. PhD; Jarolim, Petr MD, PhD; Kober, Lars MD, DMSc; Kosiborod, Mikhail N. MD; Martinez, Felipe A. MD; Ponikowski, Piotr MD, PhD; Solomon, Scott D. MD; Sjostrand, Mikaela MD, PhD; Bengtsson, Olof Ph Lic; Greasley, Peter J. PhD; Sattar, Naveed MD; Welsh, Paul PhD; Sabatine, Marc S. MD, MPH; Morrow, David A. MD, MPH; McMurray, John J.V. MD
doi : 10.1161/CIRCULATIONAHA.122.063327
ET-1 (endothelin-1) is implicated in the pathophysiology of heart failure and renal disease. Its prognostic importance and relationship with kidney function in patients with heart failure with reduced ejection fraction receiving contemporary treatment are uncertain.
Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
Tang, Yansong MD ,*; Feng, Mengying PhD ,*; Su, Yang PhD; Ma, Teng MD; Zhang, Hongjie PhD; Wu, Hongchun MS; Wang, Xiaoyu MD; Shi, Shuyue BS; Zhang, Ying BS; Xu, Yawei MD, PhD; Hu, Shijun PhD; Wei, Ke PhD; Xu, Dachun MD, PhD
doi : 10.1161/CIRCULATIONAHA.123.064121
A large portion of idiopathic and familial dilated cardiomyopathy (DCM) cases have no obvious causal genetic variant. Although altered response to metabolic stress has been implicated, the molecular mechanisms underlying the pathogenesis of DCM remain elusive.
Titin Missense Variants as a Cause of Familial Dilated Cardiomyopathy.
Dominguez, Fernando MD, PhD; Lalaguna, Laura MSc; Martinez-Martin, Ines MSc; Piqueras-Flores, Jesus MD, PhD; Rasmussen, Torsten Bloch MD, PhD; Zorio, Esther MD, PhD; Giovinazzo, Giovanna PhD; Prados, Belen PhD; Ochoa, Juan Pablo MD, PhD; Bornstein, Belen MD, PhD; Gonzalez-Lopez, Esther MD, PhD; Velazquez-Carreras, Diana MSc; Pricolo, Maria Rosaria PhD; Gutierrez-Aguera, Francisco PhD; Bernal, Juan Antonio MD, PhD; Herrero-Galan, Elias PhD; Alegre-Cebollada, Jorge PhD; Lara-Pezzi, Enrique PhD; Garcia-Pavia, Pablo MD, PhD
Letter by Doundoulakis et al Regarding Article, "Programmed Ventricular Stimulation as Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy".
Doundoulakis, Ioannis PhD; Tsioufis, Konstantinos PhD; Gatzoulis, Konstantinos A. PhD
Popular Dietary Patterns: Alignment With American Heart Association 2021 Dietary Guidance: A Scientific Statement From the American Heart Association.
Gardner, Christopher D. PhD, FAHA, Chair; Vadiveloo, Maya K. PhD, RD, FAHA, Vice Chair; Petersen, Kristina S. PhD, APD, FAHA; Anderson, Cheryl A.M. PhD, MPH, FAHA; Springfield, Sparkle PhD; Van Horn, Linda PhD, RDN, FAHA; Khera, Amit MD, MSc, FAHA; Lamendola, Cindy MSN, ANP-BC, FAHA; Mayo, Shawyntee M. MD; Joseph, Joshua J. MD, MPH, FAHA; on behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health
doi : 10.1161/CIR.0000000000001146
AB The evolution of dietary guidelines from isolated nutrients to broader dietary pattern recommendations results from growing knowledge of the synergy between nutrients and their food sources as they influence health.
